Showing results (41-50 of 61) with videos related to

Sort By:
Pageof 7
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 5, 2020
Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGSJosep Tabernero, Maria Alsina, Kohei Shitara, et al.
Drug Design, Development and Therapy|September 15, 2015
Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analoguesEdward M Wolin, Barbara Jarzab, Barbro Eriksson, et al.
Journal for Immunotherapy of Cancer|July 3, 2023
Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trialKohei Shitara, Maria Di Bartolomeo, Mario Mandala, et al.
Oncotarget|January 8, 2019
Genomic loss of heterozygosity and survival in the REAL3 trialElizabeth C Smyth, Catherine Cafferkey, Andrea Loehr, et al.
The Lancet. Oncology|April 19, 2013
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trialTom Waddell, Ian Chau, David Cunningham, et al.
The Lancet. Oncology|October 26, 2018
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trialKohei Shitara, Toshihiko Doi, Mikhail Dvorkin, et al.
The Lancet. Oncology|February 7, 2017
Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trialDavid Cunningham, Sally P Stenning, Elizabeth C Smyth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2024
First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 StudySusanna Hegewisch-Becker, Guillermo Mendez, Joseph Chao, et al.
The Oncologist|May 30, 2024
Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancerWasat Mansoor, Seongjung Joo, Josephine M Norquist, et al.
Lancet (London, England)|June 9, 2018
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trialKohei Shitara, Mustafa Özgüroğlu, Yung-Jue Bang, et al.
Pageof 7